ClinicalTrialsFinder

Resectable Esophagogastric Adenocarcinoma Clinical Trials in München

1 recruitingMünchen, Germany

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Neoadjuvant TherapyEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest18 enrolled4 locationsNCT07059299